Details for Patent: 9,908,845
✉ Email this page to a colleague
Which drugs does patent 9,908,845 protect, and when does it expire?
Patent 9,908,845 protects WELIREG and is included in one NDA.
This patent has fifty-two patent family members in twenty-eight countries.
Summary for Patent: 9,908,845
Title: | Aryl ethers and uses thereof |
Abstract: | The present disclosure relates to HIF-2.alpha. inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2.alpha. scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo. |
Inventor(s): | Dixon; Darryl David (Dallas, TX), Grina; Jonas (Coppell, TX), Josey; John A. (Dallas, TX), Rizzi; James P. (Irving, TX), Schlachter; Stephen T. (Dallas, TX), Wallace; Eli M. (Richardson, TX), Wang; Bin (Dallas, TX), Wehn; Paul (Dallas, TX), Xu; Rui (Dallas, TX), Yang; Hanbiao (Coppell, TX) |
Assignee: | PELOTON THERAPEUTICS, INC. (Dallas, TX) |
Application Number: | 14/905,776 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 9,908,845
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY | ⤷ Sign Up | ||
Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,908,845
PCT Information | |||
PCT Filed | September 05, 2014 | PCT Application Number: | PCT/US2014/054375 |
PCT Publication Date: | March 12, 2015 | PCT Publication Number: | WO2015/035223 |
International Family Members for US Patent 9,908,845
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 097600 | ⤷ Sign Up | |||
Australia | 2014318025 | ⤷ Sign Up | |||
Canada | 2919397 | ⤷ Sign Up | |||
China | 105530923 | ⤷ Sign Up | |||
China | 110372550 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |